

**Anti-uPA (human, urokinase plasminogen activator)  
 Mouse monoclonal antibody**

Subclass: IgG1

PRODUCT NO.

**MON U-16**

PRESENTATION

 Preparation: Protein-A purified  
 Content: Available in 200 µL and 1 mL volumes, 1 mg/mL  
 Solvent: 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide  
 Storage: In the dark at 4-8°C

ANTIGEN

Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development (1-3). Elevated levels of uPA are associated with poor prognosis in many types of cancer (2-5).

IMMUNOGEN

Native human uPA

SPECIFICITY

MON U-16 is specific for human uPA. No reaction with human tissue plasminogen activator (tPA) when tested by ELISA, immunoblotting and enzyme inhibition and no reaction with any other human plasma proteins when tested by immunoblotting.

EPI TOPE SPECIFICITY

MON U-16 binds to the B-chain of uPA (6)

REACTIVITY

MON U-16 binds single and two-chain uPA and uPA/PAI-1 complexes. A reaction is seen with LMW-uPA but not with amino terminal fragment (ATF). MON U-16 is recommended for flowcytometry and immunofluorescence studies (6) and can be used on frozen sections in immunohistochemistry applications.

CULTURE MEDIUM

RPMI 1640 with 10% fetal calf serum

FUSION PARTNER

NSI-Ag 4/1

IMMUNIZATION

Female BALB/c mice immunized by intradermal injection

APPLICATION

Method	Usability	Dilution guideline	References
ELISA	Yes		5
Immunoblotting	Yes		
Immunohistochemistry	Yes		

REFERENCES

- Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. *Adv Cancer Res* 44:139-266.
- Andreasen PA, Kjølner L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. *Int J Cancer* 2:1-22.
- Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J (2005) Plasminogen activation and cancer. *Thromb Haem* 93:676-681.
- Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). *Cancer Res* 62:4617-22.
- Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. *J Imm Meth* 203:55-65.
- Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. *Proc Natl Acad Sci USA* 79:3720-3723.
- Plesner T, Ploug M, Ellis V, Rønne E, Høyer-Hansen G, Wittrup M, Pedersen TL, Tscherning T, Danø K, Hansen NE (1994) The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. *Blood* 83:808-815.

**CONDITIONS**

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.